News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement
|Articles|October 25, 2011

Invitation Application for Pharma and Biotech Industry Executives:

Invitation Application for Pharma and Biotech Industry Executives:

Advertisement

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Advertisement

Related Content

Advertisement
Tommy Bramley

Asembia's AXS26 Summit: How US Regulatory Updates are Impacting Global Launch Strategies

ByMike Hollan,Tommy Bramley
April 27th 2026
Pharmaceutical Executive Daily

Pharmaceutical Executive Daily: FDA Approves Caplyta for Adults with Schizophrenia

ByNicholas Jacobus
April 27th 2026
Stock.adobe.com FDA approval

FDA Approves Caplyta for Prevention of Schizophrenia in Adults

ByNicholas Jacobus
April 27th 2026
Stock.adobe.com deal

Eli Lilly Enters $ 2.3 Billion Agreement to Acquire Ajax Therapeutics

ByNicholas Jacobus
April 27th 2026
Maher Masoud

Moving Cell and Gene Therapy Towards the Future: Q&A with Maher Masoud

ByMike Hollan,Maher Masoud
April 27th 2026
Advertisement
Advertisement

Trending on PharmExec

1

Eli Lilly Enters $ 2.3 Billion Agreement to Acquire Ajax Therapeutics

2

Moving Cell and Gene Therapy Towards the Future: Q&A with Maher Masoud

3

FDA Approves Caplyta for Prevention of Schizophrenia in Adults

4

How Can Pharma Prices be Reduced for Americans Without Impacting Innovation?

5

Regeneron Agrees to Lower Drug Costs for U.S. Patients and Provide Otarmeni for Free

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us